Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Serum MUC5AC as a dynamic biomarker for tumor response, prognosis, and risk stratification in resected pancreatic ductal adenocarcinoma.

Ashish Manne, Deepak Sherpally, Ravi Kumar Paluri et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16364

e16364 Background: There is an unmet need for novel biomarkers to guide and personalize treatment strategies for early-stage pancreatic ductal adenocarcin...

Real-world evidence of toxicity profile with cellular immunotherapy from India: Cellular insights study.

Zoya Peelay, Atanu Bhattacharjee, Bilal Kazi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14533

e14533 Background: Real-world data on adverse events (AEs) following adoptive cellular immunotherapy in India is scarce. This study evaluates the toxicity...

Neoadjuvant cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) plus chemotherapy in early or locally advanced triple-negative breast cancer: A single-arm phase II trial (CABIN study).

Tao Wu, Yong Xu, Ke Gong et al. Jun 01, 2025 pp. 599-599 10.1200/jco.2025.43.16_suppl.599

599 Background: Neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) can improve surgical outcomes; however, many patients fail to achieve pa...

The impact of burnout on oncologists and hematologists: <i>Nunc agendum est</i> (now is the time to act).

Rajesh Sharma, Priyanshi Rajesh Sharma Jun 01, 2025 pp. 9014-9014 10.1200/jco.2025.43.16_suppl.9014

9014 Background: Burnout among oncologists is a pressing global issue, with prevalence rates ranging from 25% to 70%. South Asia, in particular, has repor...

Patient-reported experience with an immunotherapy telehealth platform.

Robert Michael Daly, Charlotte Malling, Andrea DAgostino et al. Jun 01, 2025 pp. 1654-1654 10.1200/jco.2025.43.16_suppl.1654

1654 Background: The Making Teleheath Delivery of Cancer Care at Home Effective and Safe for Immunotherapy (MATCHES-IO) intervention seeks to improve the...

Survival outcomes in radioactive iodine-refractory (RAIR) differentiated thyroid cancer (DTC) with BRAF mutation: A real-world study from the Spanish Taskforce for Neuroendocrine and Endocrine Tumors (GETNE) Thyroid Cancer registry.

Alejandro Garcia-Alvarez, Jorge Hernando, Javier Martinez Trufero et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18159

e18159 Background: For BRAF V600E RAIR-DTC, the role of BRAF with or without MEK inhibitors (BRAFi; MEKi) has been studied, given the success of these the...

Safety and efficacy of venetoclax and ibrutinib in relapsed/refractory chronic lymphocytic leukemia: A systematic review and meta-analysis.

Muhammad Ahmad Sohail, Sijel Husaini, Mohammad Ismail Asim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19035

e19035 Background: Chronic lymphocytic leukemia (CLL) is considered to be the most common leukemia in adults and remains incurable but newer oral targeted...

Impact of liquid biopsy on health-related quality of life in cancer treatment: A systematic review.

Muhammad Kashif Amin, Nouman Aziz, Syed Maaz Tariq et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14538

e14538 Background: Liquid biopsy has emerged as a promising tool in cancer management, offering non-invasive methods for monitoring disease progression an...

Baseline hematological parameters and outcomes in patients with prostate cancer treated with Lu-177 PSMA radioligand therapy (RLT): A multicenter real-world analysis.

Colin P. Bergstrom, Joseph David Allen, Cameron Chalker et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17047

e17047 Background: Patients (Pts) with Prostate Cancer (PC) receiving RLT are at risk of developing cytopenias that can cause dose holds or early treatmen...

Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.

Ashley Love Sumrall, Joshua E. Allen, Stephen Joseph Bagley et al. Jun 01, 2025 pp. 10017-10017 10.1200/jco.2025.43.16_suppl.10017

10017 Background: Dordaviprone (ONC201), a first in class imipridone, has demonstrated safety and efficacy in an integrated analysis of patients with recu...

Integrative oncology interest in persons with a cancer diagnosis.

Julia Witkowski, Nikita Nikita, Ana María López Jun 01, 2025 pp. 11100-11100 10.1200/jco.2025.43.16_suppl.11100

11100 Background: Integrative oncology (IO) is an evidence-informed field of cancer care that utilizes mind-body practices, natural products, and lifestyl...

Association between the presence of malignant ascites and survival outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.

Yuna Lee, Hyung-Don Kim, Jaewon Hyung et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16057

e16057 Background: Malignant ascites is associated with poor outcomes in advanced gastric cancer, but its prognostic value has not been confirmed in the c...

Women’s breast cancer mortality trends: The impact of lifestyle factors from the 2021 Global Burden of Disease (GBD) study.

Samantha El Warrak, Chinmay Jani, Traci King et al. Jun 01, 2025 pp. 10602-10602 10.1200/jco.2025.43.16_suppl.10602

10602 Background: Breast cancer (BC) remains a leading cause of death among women globally. Understanding the role of modifiable risk factors is critical...

Preoperative PD-1 inhibitor (tislelizumab) plus SOX for locally advanced gastric or gastro-oesophageal junction cancer: Results from a single-arm, phase II trial.

Haokai Hu, Jiarui Lin, Zhenhong Weng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16140

e16140 Background: Although perioperative chemotherapy is the standard treatment regimen for locally advanced gastric cancer, the pathological complete re...

Use of STAMP-seq to enable spatial transcriptomics through single-nucleus in situ tagging and exploration of relationship of dynamic plasma cell modules and immunotherapy response in non-small cell lung cancer.

Yitong Pan, Huan Yan, Jinhuan Han et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20040

e20040 Background: Immunotherapy has revolutionized cancer treatment, particularly in non-small cell lung cancer (NSCLC), yet a large fraction of patients...

Preoperative axillary US and MRI in early-stage breast cancer: Potential to prevent unnecessary axillary surgery.

Xin Wang, Haitong Xie, Weijing Liu et al. Jun 01, 2025 pp. 577-577 10.1200/jco.2025.43.16_suppl.577

577 Background: Recent studies, including the INSEMA and SOUND trials, have demonstrated that omitting sentinel lymph node (SLN) biopsy does not adversely...

Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.

Wenfeng Fang, Qiming Wang, Ying Cheng et al. Jun 01, 2025 pp. 8529-8529 10.1200/jco.2025.43.16_suppl.8529

8529 Background: Sac-TMT (MK-2870/SKB264) is a TROP2 ADC developed with a novel linker to conjugate a belotecan-derivative...

Outcomes of follicular lymphoma patients hospitalized with viral respiratory illnesses: A national population-based study.

Abdulsabur Sanni, Amro Awad Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19066

e19066 Background: Follicular lymphoma (FL) is an indolent B cell disorder with improving OS with the evolution of new drug agents. Prior studies have sho...

Accrual of historically underrepresented patients with multiple myeloma using centralized screening in a multicenter study.

Anosheh Afghahi, Daniel P. Sanchez, Yichen Lu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13709

e13709 Background: Patient (pt) identification, which is resource-intensive and time-consuming, can impede accrual to oncology trials, particularly in com...

Evaluating multiplex immunofluorescence analysis of the tumor microenvironment for predicting immunotherapy efficacy in NSCLC compared to traditional biomarkers.

Edoardo Garbo, Joao Victor Machado Alessi, Biagio Ricciuti et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20600

e20600 Background: Only a subset of patients (pts) with advanced non-small cell lung cancer (aNSCLC) benefits from treatment with immune checkpoint inhibi...

Combined preoperative segmental hepatic arteries embolization with hepatic artery resection in radical pancreatic resections for locally advanced pancreatic cancer.

Yu Mou, Shengzhong Hou, Xing Huang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16386

e16386 Background: Locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) combined with hepatic arteries invasion is usually considered unresectable....

A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.

Michael Paul Kolinsky, Kim N. Chi, Sebastien J. Hotte et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5122

TPS5122 Background: For patients (pts) with mCRPC there are numerous treatment options including single agent docetaxel after treatment with androgen rece...

Personalized targeted glioblastoma therapies by <i>ex vivo</i> drug screening: Advanced brain tumor therapy clinical trial (ATTRACT).

Anna Sophie Berghoff, Matthias Preusser, Maximilian Mair et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps2097

TPS2097 Background: Targeted therapies used in a personalized treatment concept have revolutionized the management of several solid cancers. So far, vario...

Enhancing variant interpretation in hereditary cancer testing with RNA analysis from residual blood samples.

Paola Nix, Erin Mundt, Shelly Ann Cummings et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22595

e22595 Background: Functional RNA studies can enable definitive classification for DNA variants of uncertain significance (VUS) identified via hereditary...

Modified four-quadrant enhanced coloanal anastomosis (fqeCAA) for patients receiving intersphincteric resection.

Wenchao Cao, Mingtian Wei, Yu Shen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15620

e15620 Background: Intersphincteric resection (ISR) is a sphincter-preserving surgery for ultra-low rectal cancer (uLRC). The anastomosis techniques for I...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page